LLY

1,141

+2.65%↑

ABBV

228.27

+3.64%↑

UNH

398.61

+0.22%↑

MRK

120.63

+1.46%↑

AZN

184.68

+2.29%↑

LLY

1,141

+2.65%↑

ABBV

228.27

+3.64%↑

UNH

398.61

+0.22%↑

MRK

120.63

+1.46%↑

AZN

184.68

+2.29%↑

LLY

1,141

+2.65%↑

ABBV

228.27

+3.64%↑

UNH

398.61

+0.22%↑

MRK

120.63

+1.46%↑

AZN

184.68

+2.29%↑

LLY

1,141

+2.65%↑

ABBV

228.27

+3.64%↑

UNH

398.61

+0.22%↑

MRK

120.63

+1.46%↑

AZN

184.68

+2.29%↑

LLY

1,141

+2.65%↑

ABBV

228.27

+3.64%↑

UNH

398.61

+0.22%↑

MRK

120.63

+1.46%↑

AZN

184.68

+2.29%↑

Home・Aandelen Lijst・Johnson and Johnson

Johnson and Johnson

Gesloten

SectorGezondheidszorg

229.63 1.58

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

226.23

Max

231.2

Belangrijke statistieken
By Trading Economics
Inkomsten	119M 5.2B
Verkoop	-502M 24B
K/W Sectorgemiddelde	25.899 49.888
EPS	2.7
Dividendrendement	2.31
Winstmarge	21.756
Werknemers	138,200
EBITDA	182M 6.4B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+16.76% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.31% 2.38%
Volgende Winsten	15 jul 2026
Volgende dividenddatum	9 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-35B 538B
Vorige openingsprijs	228.05
Vorige sluitingsprijs	229.63

Nieuwssentiment

By Acuity

22%

78%

45 / 344 Rangschikking in Healthcare

Johnson and Johnson Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 13:27 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 apr 2026, 11:27 UTC

Winsten

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 apr 2026, 19:38 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 14:13 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 12:57 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 11:19 UTC

Winsten

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 apr 2026, 10:34 UTC

Winsten

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 apr 2026, 10:20 UTC

Marktinformatie

Winsten

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 apr 2026, 10:20 UTC

Marktinformatie

Winsten

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 apr 2026, 10:20 UTC

Winsten

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Peer Vergelijking

Prijswijziging

Johnson and Johnson Prognose

Koersdoel

By TipRanks

16.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 266.4 USD 16.76%

Hoogste 285 USD

Laagste 250 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Johnson and Johnson - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Johnson and Johnson - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

45 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.